

# Lucija ViroviÄ JukiÄ

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5434800/publications.pdf>

Version: 2024-02-01

13  
papers

559  
citations

1478505

6  
h-index

1199594

12  
g-index

13  
all docs

13  
docs citations

13  
times ranked

1034  
citing authors

#	ARTICLE	IF	CITATIONS
1	Adipokines and proinflammatory cytokines, the key mediators in the pathogenesis of nonalcoholic fatty liver disease. <i>World Journal of Gastroenterology</i> , 2014, 20, 18070.	3.3	260
2	Pathogenesis and management issues for non-alcoholic fatty liver disease. <i>World Journal of Gastroenterology</i> , 2007, 13, 4539.	3.3	223
3	Coagulation and Endothelial Dysfunction Associated with NAFLD: Current Status and Therapeutic Implications. <i>Journal of Clinical and Translational Hepatology</i> , 2022, 10, 339-355.	1.4	16
4	Non-alcoholic fatty liver disease â€œ a procoagulant condition?. <i>Croatian Medical Journal</i> , 2021, 62, 25-33.	0.7	15
5	Post-transplant diabetes mellitus and preexisting liver disease - a bidirectional relationship affecting treatment and management. <i>World Journal of Gastroenterology</i> , 2020, 26, 2740-2757.	3.3	14
6	Prevalence and Prognostic Impact of Deranged Liver Blood Tests in COVID-19: Experience from the Regional COVID-19 Center over the Cohort of 3812 Hospitalized Patients. <i>Journal of Clinical Medicine</i> , 2021, 10, 4222.	2.4	12
7	FibroScan-AST Score Predicts 30-Day Mortality or Need for Mechanical Ventilation among Patients Hospitalized with COVID-19. <i>Journal of Clinical Medicine</i> , 2021, 10, 4355.	2.4	5
8	Plexiglas barrier box to improve ERCP safety during the COVID-19 pandemic. <i>Gastrointestinal Endoscopy</i> , 2020, 92, 428-429.	1.0	4
9	Risk Factors for Colorectal Adenoma â€œ Acknowledging the Burden of NAFLD. <i>Journal of Clinical and Translational Hepatology</i> , 2019, 7, 97-98.	1.4	3
10	New Drugs on the Blockâ€”Emerging Treatments for Nonalcoholic Steatohepatitis. <i>Journal of Clinical and Translational Hepatology</i> , 2020, 000, 1-9.	1.4	3
11	Metabolism of Direct-acting Antiviral Agents (DAAs) in Hepatitis C Therapy: A Review of the Literature. <i>Current Drug Metabolism</i> , 2021, 22, 89-98.	1.2	2
12	The Accuracy of Serum Biomarkers in the Diagnosis of Steatosis, Fibrosis, and Inflammation in Patients with Nonalcoholic Fatty Liver Disease in Comparison to a Liver Biopsy. <i>Medicina (Lithuania)</i> , 2022, 58, 252.	2.0	2
13	Croatian guidelines for the diagnosis and treatment of nonalcoholic fatty liver disease. <i>Acta Clinica Croatica</i> , 2021, 60, 36-52.	0.2	0